KiribatiTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.054 (0.044–0.065) 49 (40–59)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.83 (0.41–1.4) 749 (375–1 250)
Incidence  (includes HIV+TB) 0.55 (0.45–0.66) 497 (406–597)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 1.7 (1.3–2.1)
         
Case detection, all forms (%) 75 (63–92)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.6–6.4) 23 (20–26)
MDR-TB cases among notified pulmonary
TB cases
16 (9–22) 6 (6–7)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 151   10
Pulmonary, clinically diagnosed 198   0
Extrapulmonary 55   0
       
Total new and relapse 414    
Previously treated, excluding relapses 18    
Total cases notified 432    
Among 414 new and relapse cases:
95 (23%) cases aged under 15 years; male:female ratio: 1.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 22 (79%) 22
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 223 (52)
HIV-positive TB patients 1 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (100)
HIV-positive people screened for TB 2  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (86) 394
Previously treated cases, excluding relapse, registered in 2013 (88) 16
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 45.3
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically  
% Funded internationally  
% Unfunded 100%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-28 Data: www.who.int/tb/data